Radiopharm Theranostics Secures Lutetium-177 Supply Agreement with ITM

The latest announcement is out from Radiopharm Theranostics Limited Sponsored ADR ( (RADX) ).

On May 19, 2025, Radiopharm Theranostics announced a supply agreement with ITM Isotope Technologies Munich SE for the provision of ITM’s non-carrier-added Lutetium-177. This agreement will support Radiopharm’s clinical pipeline, including key programs targeting solid tumors, by ensuring a reliable supply of this critical radioisotope. The collaboration is expected to enhance Radiopharm’s ability to advance its therapeutic candidates, reflecting a shared commitment to improving cancer treatment options.

The most recent analyst rating on (RADX) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited Sponsored ADR stock, see the RADX Stock Forecast page.

More about Radiopharm Theranostics Limited Sponsored ADR

Radiopharm Theranostics is a clinical stage radiotherapeutics company focused on developing a platform of innovative radiopharmaceutical products for both diagnostic and therapeutic applications, particularly in areas with high unmet medical needs. The company is listed on the ASX and NASDAQ and has a pipeline that includes peptides, small molecules, and monoclonal antibodies for treating various solid tumor cancers.

Average Trading Volume: 184,632

Current Market Cap: $32.89M

For detailed information about RADX stock, go to TipRanks’ Stock Analysis page.